

Review of: "Resectable Pancreatic Cancer With Peritoneal Metastases: Is Cytoreduction Combined With Hipec Effective and When?"

David Morris¹

¹ University of New South Wales

Potential competing interests: No potential competing interests to declare.

This is a very interesting topic, and any data is valuable. This small series provides some support for HIPEC in peritoneal cancer, but it is of course not an RCT, and at 3 years, 80% of patients had recurred and died. It would be interesting to know the features of the few patients (?1-2) who have not.

There is, I think, an English error on page 7, line 10. I expect laparoscopy was intended.